The Journal of Immunology, Vol 143, Issue 1 162-167, Copyright © 1989 by American Association of Immunologists

ARTICLES

In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice

JK McIntosh, DM Jablons, JJ Mule, RP Nordan, S Rudikoff, MT Lotze and SA Rosenberg
Surgery Branch, National Cancer Institute, Bethesda, MD 20892.

We investigated the capacity of several recombinant cytokines to induce IL-6 in vivo in both normal and tumor-bearing (TB) mice. Intravenous administration of human rhTNF-alpha, rhIL-1, rhIL-2, rhIFN-alpha A/D, and rmIFN-gamma were all capable of inducing circulating IL-6. rhTNF- alpha administration caused the greatest induction of IL-6. TB animals consistently produced more IL-6 in response to rhTNF-alpha than did normal mice (2 h after 4 micrograms rhTNF-alpha, TB = 24,100 HGF U/ml, non-TB = 3600 HGF U/ml of IL-6). A single daily i.v. dose of rhTNF- alpha (4 micrograms/mouse/day) for 5 days led to decreased IL-6 induction in TB animals by day 3 of treatment (peak levels of IL-6, day 1 = 72,800 HGF U/ml, day 3 = 23,400 HGF U/ml, day 5 = 26,400 HGF U/ml). rhIL-1 administration also resulted in considerable IL-6 production, although peak values were less than those resulting from administration of rhTNF-alpha. Administration of rhIL-1 induced similar IL-6 levels (TB = 10,025 and non-TB = 10,600 HGF U/ml) in TB and normal mice. Single high doses of rhIL-2, rhIFN-alpha A/D, and rmIFN-gamma induced lower but consistent levels of circulating IL-6 in mice with and without tumor. In addition, the sera of untreated TB mice contained levels of IL-6 which paralleled the extent of tumor burden (serum IL-6 in day 30 MCA 106 TB mice = 420 HGF U/ml). The detection of de novo IL- 6 was also confirmed in animals bearing tumors of different histologies (the MCA 102 sarcoma, MCA 38 adenocarcinoma, and B16 melanoma). At no time was IL-6 measurable in the sera of untreated normal mice. The identification of IL-6 was verified by neutralization studies using specific antimurine IL-6 antibody. Although the exact role of IL-6 in TB animals remains to be elucidated, its known pleotrophic immune and metabolic effects may be important in the host response to malignancy.

This article has been cited by other articles:

				K. Hayashida, Y. Chen, A. H. Bartlett, and P. W. Park Syndecan-1 Is an in Vivo Suppressor of Gram-positive Toxic Shock J. Biol. Chem., July 18, 2008; 283(29): 19895 - 19903. [Abstract] [Full Text] [PDF]

				W. Wang, C. Lonnroth, E. Svanberg, and K. Lundholm Cytokine and Cyclooxygenase-2 Protein in Brain Areas of Tumor-bearing Mice with Prostanoid-related Anorexia Cancer Res., June 1, 2001; 61(12): 4707 - 4715. [Abstract] [Full Text] [PDF]

				D. Agnello, C. Meazza, C. G. Rowan, P. Villa, P. Ghezzi, and G. Senaldi Leptin causes body weight loss in the absence of in vivo activities typical of cytokines of the IL-6 family Am J Physiol Regulatory Integrative Comp Physiol, September 1, 1998; 275(3): R913 - R919. [Abstract] [Full Text] [PDF]

				S. P. Hauser, O. Kajkenova, and D. A. Lipschitz The Pivotal Role of Interleukin 6 in Formation and Function of Hematopoietically Active Murine Long-Term Bone Marrow Cultures Stem Cells, March 1, 1997; 15(2): 125 - 132. [Abstract] [Full Text]

				C. Gordon and P. Emery Cytokines and the Acute Phase Response in SLE Lupus, December 1, 1993; 2(6): 345 - 347. [PDF]

				C. Meijer, V. Huysen, R.T.J. Smeenk, and A.J.G. Swaak Profiles of Cytokines (TNF{alpha} and IL-6) and Acute Phase Proteins (CRP and {alpha}1AG) related to the Disease Course in Patients with Systemic Lupus Erythematosus Lupus, December 1, 1993; 2(6): 359 - 365. [Abstract] [PDF]

				O. GALLO, A. M. GORI, M. ATTANASIO, F. MARTINI, G. PAOLA, O. F. STORCHI, and R. ABBATE Acute-Phase Proteins and Interleukin 6 Serum Level in Head and Neck Cancer Arch Otolaryngol Head Neck Surg, December 1, 1992; 118(12): 1366 - 1366. [Abstract] [PDF]